Xeris (XERS) CFO reports new RSU grant, options and tax withholding

Rhea-AI Filing Summary

Xeris Biopharma Holdings reported insider equity awards and related tax share withholding for Chief Financial Officer Steven Pieper. On January 30, 2026, he received 154,986 shares of common stock through a restricted stock unit grant under the 2018 Stock Option and Incentive Plan, vesting in equal annual installments over three years, subject to continued employment.

On the same date, he was granted 207,207 stock options with an exercise price of $7.36 per share, also vesting annually over three years and expiring on January 30, 2036. On January 31, 2026, a total of 206,?

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pieper Steven

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		154,986(1)	A	$0	1,572,547	D
Common Stock	01/31/2026		F		111,765(2)	D	$7.36	1,460,782	D
Common Stock	01/31/2026		F		66,450(2)	D	$7.36	1,394,332	D
Common Stock	01/31/2026		F		27,319(2)	D	$7.36	1,367,013	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.36	01/30/2026		A		207,207		(3)	01/30/2036	Common Stock	207,207	$0	207,207	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.

2. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.

3. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

Chief Financial Officer

	/s/ Beth Hecht, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Xeris (XERS) report for CFO Steven Pieper?

Xeris reported equity awards and tax-related share withholding for CFO Steven Pieper. He received 154,986 shares from a restricted stock unit grant and 207,207 stock options, and shares were withheld to cover taxes on vested restricted stock units.

How many restricted stock units did the Xeris CFO receive in this Form 4?

The CFO received 154,986 restricted stock units, each representing one share of common stock. These units were granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan and vest in equal annual installments over three years, subject to continued employment.

What are the terms of the stock options granted to the Xeris CFO?

The Form 4 shows 207,207 stock options granted with a $7.36 exercise price. These options were issued under the 2018 Stock Option and Incentive Plan, vest in equal annual installments over three years, and expire on January 30, 2036, subject to continued service.

Why did Xeris withhold shares from the CFO’s holdings in this filing?

Shares were withheld to satisfy income tax and withholding obligations on vested restricted stock units. The filing notes that the withheld shares relate to the net settlement of restricted stock units that vested as of January 31, 2026, rather than open-market sales by the CFO.

How many Xeris common shares does the CFO hold after these transactions?

After the reported transactions, the Form 4 shows Steven Pieper beneficially owning 1,367,013 shares of Xeris common stock directly. He also holds 207,207 stock options, each exercisable for one share of common stock under the company’s equity incentive plan.

Is the Xeris CFO’s transaction a routine equity compensation event?

The filing reflects routine equity compensation activity, including a new restricted stock unit grant, a stock option grant, and shares withheld for taxes on vested units. All awards and withholdings are under Xeris Biopharma’s 2018 Stock Option and Incentive Plan, with standard time-based vesting.